8 minute read
Sep. 21, 2023
An Azetidine-Containing, First-in-Class CCR4 Candidate with a 72 h Human Half-life
FLX475
oral CCR4 antagonist Ph. II for immunooncology, 100 mg QD from optimization of prior CCR4 ligands J. Clin. Oncol., June 1, 2023 RAPT Therapeutics, South San Francisco, CA
Author:
Editor:
Loading...
